Eli Lilly's oral tirzepatide pill: what the Phase 3 data actually shows

What did @cbsmornings actually say?

The segment covered Eli Lilly's Phase 3 trial data for orforglipron, a daily GLP-1 receptor agonist pill. The reporter said people on the highest dose lost "an average of 27 pounds over 72 weeks," called that "on par" with injectables, flagged that the data hasn't been peer-reviewed yet, noted roughly 10% of highest-dose participants stopped due to side effects, and predicted FDA submission later in 2025 with consumer availability in 2026. They also made the case that pills would be cheaper to manufacture and easier to use than injectables. No price has been announced.

This is a fairly responsible summary of a press release, and the reporter did something most health influencers skip entirely: they explicitly said the data is unpublished and unreviewed. That matters.

Does the science back this up?

The 27-pound figure is consistent with what Lilly announced, but "on par with injectables" needs more precision. Tirzepatide injections (Zepbound) produced weight loss of around 20-22% of body weight in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM). The orforglipron press release reports roughly 7.9% body weight reduction at the highest oral dose, which is lower in percentage terms than injectable tirzepatide.

That said, orforglipron is a non-peptide small molecule, meaning it doesn't require refrigeration and can be manufactured more cheaply, points the reporter made correctly. Earlier Phase 2 data (Wharton et al., 2023, NEJM) showed dose-dependent weight loss up to 14.7% over 36 weeks at higher doses with semaglutide comparisons, suggesting the oral GLP-1 class has real efficacy. But comparing a press-release number to a peer-reviewed RCO requires caution, and the reporter's framing of "on par" oversimplifies.

What did they get wrong (or right)?

They got the caveat right. Saying the data is unreviewed and came from a press release is the correct thing to say, and it's refreshing. The side effect profile they described, nausea, vomiting, diarrhea, constipation, is accurate and consistent with GLP-1 class effects documented across multiple trials (Kushner et al., 2020, Lancet).

Where the segment is loose: the claim that pills are "a lot cheaper to manufacture" is plausible chemistry, but it doesn't mean cheaper for the patient. Lilly's pricing on Zepbound and Mounjaro has faced intense criticism, and there is zero announced pricing for orforglipron. Conflating manufacturing cost with consumer cost is a meaningful error that could create false expectations. Also, the "no restrictions around food or water" claim is specific to orforglipron's profile and shouldn't be generalized to all oral GLP-1s, semaglutide tablets (Rybelsus) require fasting and water restrictions.

The 10% discontinuation rate at the highest dose is worth flagging more than the segment did. That's a clinically relevant tolerability signal, not a footnote.

What should you actually know?

Orforglipron is not approved. This is Phase 3 press-release data, the weakest form of clinical evidence outside of anecdote. Peer review exists for a reason, and GLP-1 trial histories have included surprises when full data surfaces (cardiovascular signals, for instance, took years to characterize).

The convenience argument is real. Needle aversion is a documented barrier to GLP-1 uptake (Hauber et al., 2016, Diabetes Care), and an oral option that doesn't require refrigeration could meaningfully expand access in lower-resource settings. That's a legitimate public health point.

But "accessible" and "affordable" are not the same word. Until Lilly publishes pricing, the affordability framing is speculative. Injectable GLP-1s in the US cost over $1,000 per month without insurance. Manufacturing economics don't always translate to sticker price in the American pharmaceutical market, and there's no evidence yet that they will here.

If you're a current GLP-1 user or candidate, orforglipron is not a reason to change your treatment plan today. Talk to a licensed provider about what's available now.